Cabergoline
A dopamine receptor agonist derived from ergot used to treat conditions of elevated prolactin including prolactinomas, and also for Parkinson's disease. It suppresses prolactin secretion from the pituitary gland, reducing symptoms such as irregular periods and unwanted milk production. Long-term use at high doses has been associated with cardiac valve abnormalities.
Peso Molecular
451,6000 g/mol
LogP
3,40
TPSA
71,70 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
InChI
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
Molecular Formula
C26H37N5O2
HBD / HBA
2 / 4
Ligações Rotacionáveis
8
Átomos Pesados
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A dopamine receptor agonist derived from ergot used to treat conditions of elevated prolactin including prolactinomas, and also for Parkinson's disease. It suppresses prolactin secretion from the pituitary gland, reducing symptoms such as irregular periods and unwanted milk production. Long-term use at high doses has been associated with cardiac valve abnormalities.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Cabergoline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201087. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54746. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabergoline"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabergoline/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabergoline/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabergoline/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabergoline"></drugfyi-drug>